Low Testosterone Therapy Lawsuit Attorneys

Lawyers for Low Testosterone Therapy Claims

Because testosterone levels in men gradually decline with age, companies such as AbbVie and Eli Lilly & Co. manufacture and market products to boost or replace testosterone. “Low T” drugs refers to the drugs that replace or boost testosterone in men. Products such as AndroGel, Androderm and Axiron currently face more than 6000 testosterone lawsuits in the testosterone multidistrict litigation because drugs used for testosterone therapy have been linked to serious side effects such as blood clots, stroke and heart attacks. If you have suffered these types of injuries after taking low testosterone therapy drugs,call Simmons and Fletcher, P.C. for a free consultation regarding your potential claim. 1-800-298-0111.

What is AndroGel, Androderm and Axiron?

AndroGel, currently manufactured by AbbVie’s parent company Abbott Laboratories, is one of the most prescribed gel medicines to treat low testosterone levels. After spending close to $80 million on marketing campaigns for AndroGel, AbbVie faces a growing number of lawsuits by men who suffered severe cardiac side effects. Axiron is a similar gel manufactured by Eli Lilly & Co., and has also been named in lawsuits over adverse side effects. Androderm is a testosterone transdermal patch manufactured by Actavis Inc., which was approved by the FDA in 1990. The purpose of a testosterone patch is to deliver testosterone continuously for 24 hours.

Dangerous Effects of Low Testosterone Therapy

While Low T therapy is intended to increase strength, sex drive and vitality in men; it can also cause severe cardiac effects such as blood clots and heart attacks. It wasn’t until 2015 that the FDA announced labeling changes for all prescription testosterone products to state the increased risk of heart attacks and strokes. Today thousands of men suffer from injuries caused by products such as AndroGel, Androderm and Axiron.

Bellweather Trials Continue for Low T Drugs

In January 2018, the sixth and final bellwether trial for AbbVie’s AndroGel is expected to begin. The second bellwether trial, which began on July 2017, ended in a $150 million verdict against the manufacturer after Jeffrey Konrad suffered heart attack just months after taking AndroGel. Plaintiffs suing AbbVie claim that the manufacturer failed to warn patients and doctors about the increased risk of cardiac effects caused by Low T drugs.

Low Testosterone Therapy Lawsuit Attorneys

If you or a loved one has suffered from severe side effects after using AndroGel, Androderm or Axiron, you may be entitled to damages. Simmons and Fletcher, P.C. is dedicated to helping these men find justice for any injuries they may have sustained while seeking medical treatment. Call us today to set up a free Low T consultation: 800-298-0111.

Spread the love

Author

Paul Cannon

Paul Cannon has practiced personal injury trial law since 1995. He is Board Certified in Personal Injury Trial Law (2005). He has earned recognition as a Super Lawyer by Thompson Reuters in 2017 & 2018, and as a Top 100 Trial Lawyer by the National Trial Lawyers Association in 2017. He is a Shareholder, trial lawyer and online marketing manager at Simmons and Fletcher, P.C. His legal writings have been published by the Texas Bar Journal, Business.com, Lawyer.com HG Legal Resources, Lawfirms.com, and others. He has been asked to give education talks and media interviews on dog bite law.